Intra-tracheal Instillation of Budesonide Along With Surfactant in Preterm Infants to Prevent Chronic Lung Disease
Overview
- Phase
- Phase 4
- Intervention
- Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
- Conditions
- Infant, Extremely Premature
- Sponsor
- University of Arizona
- Enrollment
- 25
- Locations
- 1
- Primary Endpoint
- Change of combined inflammatory cytokines
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
Preterm infants are randomized to received either Intra-tracheal instillation of budesonide using surfactant as vehicle or a placebo. Intra-tracheal instillation of budesonide using surfactant as vehicle would facilitate its delivery to the periphery of the lung and would inhibit lung inflammation and mitigate acute lung injury.
Detailed Description
In extremely premature infants who are ventilated there is ongoing lung injury \& lung inflammation. This can perpetuate the need for ongoing ventilation and these infants spend much longer in the hospital. The likelihood of chronic lung disease in this susceptible group is very high and they would need oxygen at home. Surfactant instillation has reduced the need for prolonged mechanical ventilation and to an extent the incidence of chronic lung disease (CLD). But many infants develop CLD and need prolonged oxygen treatment, diuretics and inhaled steroids to suppress the inflammation and obstruction of the airways. Some of the severely affected infants need orally administered steroids. The Inestigators propose to provide a dose of steroids instilled along with the surfactant in the very first day of life so as to prevent the vicious and ongoing cascade of lung injury and inflammation. As it is a poorly absorbed steroid and as only one or two doses is proposed to be used there is no effects within the body and it works locally within the lung. This is hoped to reduce CLD and improve long term outcomes. The population most susceptible to CLD is the extreme preterm infant with RDS who needs mechanical ventilation soon after birth. One of the groups will receive the surfactant with saline and the other group will receive the surfactant along with topical steroid. The groups will be followed during the hospital stay. survival along with duration of ventilation, duration of hospital stay and oxygen needs are noted. To study the hoped for long term benefits the investigators would note the long term neuro-development - if they were followed as per hospital policy between 18 months and 26 months. Intra-tracheal instillation of budesonide using surfactant as vehicle would facilitate its delivery to the periphery of the lung and would inhibit lung inflammation.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Infants born at \< 30+0/7 weeks (23+0 - 29+6/7) gestational age (GA) OR with preterm infants with a birth weight (BW) which is \< 1500 gm AND if they have severe respiratory distress syndrome (RDS) (Clinical diagnosis based on the need for mechanical ventilation in preterm infant or if they have radiologic features of RDS along with need for positive distending airway pressure and fractional inspired oxygen (FiO2) \> 0.3)
Exclusion Criteria
- •major congenital defects
- •chromosomal abnormality
- •pneumothorax
- •Known surgical disease
- •Known or suspected congenital heart disease
- •Infant not considered viable by physician
- •Severe sepsis / infections
- •Likely to be extubated within the next 24 hours
Arms & Interventions
S/B group- infants
Infants randomized to the study group (S/B group) will receive surfactant and Budesonide - 0.5 mg -1mL
Intervention: Infants in the study group (S/B group) will receive surfactant 2.5 mls/kg and Budesonide 0.5 mg (1mL)
S/P group- control / placebo comparator
Infants randomized to the control group (S/P group) will receive surfactant and placebo (Normal Saline -1mL)
Intervention: Infants in the control group (S/P group) receive placebo (Normal saline 1mL)
Outcomes
Primary Outcomes
Change of combined inflammatory cytokines
Time Frame: 4 weeks
Change in inflammatory cytokines /chemokines (interleukin-6, 8, 10 and Tumor Necrosis Factor α (TNF-α) levels
Secondary Outcomes
- Neuro-developmental outcome(18 - 26 months corrected postnatal age)
- chronic lung disease(36 weeks corrected gestational age (CGA))
- Ventilator days(Upto 40 weeks corrected gestational age (CGA))
- Mortality(upto 40 weeks corrected gestational age (CGA))